B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-05-06 · RankAlpha Sentiment Codex
OPCH
Option Care HealthCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-06 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-05-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-06
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+58.8
Score
AI commentary
Primary-source evidence points to a cautious rather than broken thesis: Q1 exposed a real revenue-growth problem, and recent headlines were negative, including a selloff framed around disappointing growth. The $21.30 anchor implies the market has already repriced materially lower after the April 30 update, but fresh analyst revision coverage in the packet is limited, so confidence should stay moderate-low until a post-cut estimate reset and another operating datapoint arrive.
RankAlpha Sentiment Codex - 2026-05-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08catalystChief Growth Officer departure raises execution sensitivityMedium impact
The company disclosed that Chief Growth Officer Christopher L. Grashoff will depart effective May 8, 2026, immediately after a quarter where management said it was not satisfied with revenue growth momentum. That does not change the franchise by itself, but it raises near-term scrutiny on commercial execution and referral growth. [#8-K-2026-05-05]
2026-08-04eventQ1 growth reset and lowered 2026 revenue outlookHigh impact
Q1 net revenue rose 1.3% to $1.351B, but gross profit fell 0.4% and management said chronic inflammatory disease dynamics, patient attrition, and unfavorable therapy mix should reduce 2026 gross profit by about $55M; full-year revenue guidance was reset to $5.675B-$5.775B. The next debate is whether acute growth and corrective actions can offset chronic mix pressure. [#10-Q-2026-04-30]
2026-12-31catalystEarnings resilience and liquidity partially offset top-line pressureHigh impact
Despite the revenue reset, management maintained full-year adjusted EPS guidance of $1.82-$1.92 and adjusted EBITDA guidance of $480M-$505M, while the revolver was expanded to $850M and the board-authorized repurchase capacity remains large. That supports downside cushioning if execution stabilizes. [#10-Q-2026-04-30]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-06 • Updated nightlySource: Internal modelMethodology